Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality wi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364322000595 |
| _version_ | 1828286233647775744 |
|---|---|
| author | Christine M. Bestvina, MD Jennifer G. Whisenant, PhD Valter Torri, MD Alessio Cortellini, MD Heather Wakelee, MD Solange Peters, MD, PhD Elisa Roca, MD, PhD Alessandro De Toma, MD Fred R. Hirsch, MD Hirva Mamdani, MD Balazs Halmos, MD Oscar Arrieta, MD Anne-Cecile Metivier, MD Mary J. Fidler, MD Jacobo Rogado, MD Carolyn J. Presley, MD, MHS Celine Mascaux, MD Carlo Genova, MD, PhD Juan Bautista Blaquier, MD Alfredo Addeo, MD Giovanna Finocchiaro, MD Hina Khan, MD Julien Mazieres, MD, PhD Floriana Morgillo, MD, PhD Jair Bar, MD Avinash Aujayeb, MBBS Giannis Mountzios, MD, PhD Vieri Scotti, MD Federica Grosso, MD Erica Geraedts, MD Ardak N. Zhumagaliyeva, MD, PhD Leora Horn, MD Marina Chiara Garassino, MD Javier Baena, MD |
| author_facet | Christine M. Bestvina, MD Jennifer G. Whisenant, PhD Valter Torri, MD Alessio Cortellini, MD Heather Wakelee, MD Solange Peters, MD, PhD Elisa Roca, MD, PhD Alessandro De Toma, MD Fred R. Hirsch, MD Hirva Mamdani, MD Balazs Halmos, MD Oscar Arrieta, MD Anne-Cecile Metivier, MD Mary J. Fidler, MD Jacobo Rogado, MD Carolyn J. Presley, MD, MHS Celine Mascaux, MD Carlo Genova, MD, PhD Juan Bautista Blaquier, MD Alfredo Addeo, MD Giovanna Finocchiaro, MD Hina Khan, MD Julien Mazieres, MD, PhD Floriana Morgillo, MD, PhD Jair Bar, MD Avinash Aujayeb, MBBS Giannis Mountzios, MD, PhD Vieri Scotti, MD Federica Grosso, MD Erica Geraedts, MD Ardak N. Zhumagaliyeva, MD, PhD Leora Horn, MD Marina Chiara Garassino, MD Javier Baena, MD |
| author_sort | Christine M. Bestvina, MD |
| collection | DOAJ |
| description | Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality. |
| first_indexed | 2024-04-13T09:28:49Z |
| format | Article |
| id | doaj.art-40def45b1dee4cd69aa88c393bc82c35 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-04-13T09:28:49Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-40def45b1dee4cd69aa88c393bc82c352022-12-22T02:52:20ZengElsevierJTO Clinical and Research Reports2666-36432022-08-0138100335Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT AnalysisChristine M. Bestvina, MD0Jennifer G. Whisenant, PhD1Valter Torri, MD2Alessio Cortellini, MD3Heather Wakelee, MD4Solange Peters, MD, PhD5Elisa Roca, MD, PhD6Alessandro De Toma, MD7Fred R. Hirsch, MD8Hirva Mamdani, MD9Balazs Halmos, MD10Oscar Arrieta, MD11Anne-Cecile Metivier, MD12Mary J. Fidler, MD13Jacobo Rogado, MD14Carolyn J. Presley, MD, MHS15Celine Mascaux, MD16Carlo Genova, MD, PhD17Juan Bautista Blaquier, MD18Alfredo Addeo, MD19Giovanna Finocchiaro, MD20Hina Khan, MD21Julien Mazieres, MD, PhD22Floriana Morgillo, MD, PhD23Jair Bar, MD24Avinash Aujayeb, MBBS25Giannis Mountzios, MD, PhD26Vieri Scotti, MD27Federica Grosso, MD28Erica Geraedts, MD29Ardak N. Zhumagaliyeva, MD, PhD30Leora Horn, MD31Marina Chiara Garassino, MD32Javier Baena, MD33Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; Corresponding author. Address for correspondence: Christine Bestvina, MD, Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637.Vanderbilt University Medical Center, Nashville, TennesseeOncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDepartment of Surgery and Cancer, Imperial College London, London, United KingdomStanford Cancer Institute, Stanford University, Stanford, CaliforniaLausanne University Hospital, Lausanne University, Lausanne, SwitzerlandThoracic Oncology—Lung Unit, Ospedale Pederzoli, Peschiera d/G, Verona, ItalyThoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, ItalyCenter for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New YorkDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MichiganDivision of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New YorkThoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, MexicoDepartment of Pneumology, Hopital Foch, Suresnes, FranceDepartment of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, IllinoisSeccion de Oncologia Medica, Hospital Universitario Infanta Leonor, Madrid, SpainDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OhioService De Pneumologie, Hopitaux Universitaires De Strasbourg, Strasbourg, France; Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer), Inserm UMR_S 1113, IRFAC, ITI InnoVec, Universite De Strasbourg, Strasbourg, FranceUOC Clinica di Oncologia Medica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genoa, Italy; Dipartimento di Medicina Interna e Specialita Mediche (DIMI), Universita degli Studi di Genova, Genoa, ItalyThoracic Oncology Section, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, ArgentinaUniversity Hospital of Geneva, Geneva, SwitzerlandIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, ItalyThe Warren Alpert Medical School of Brown University, Providence, Rhode IslandToulouse University Hospital, Université Paul Sabatier, Toulouse, FranceDepartment of Precision Medicine, Medical Oncology and Haematology, Universita degli studi della Campania “L. Vanvitelli,” Naples, ItalyInstitute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, IsraelRespiratory Department, Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, United KingdomFourth Department of Medical Oncology and Clinical Trials Unit Henry Dunant Hospital Center, Athens, GreeceDepartment of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, ItalyMesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, ItalyGroene Hart Ziekenhuis, Gouda, The NetherlandsSemey Medical University, Center for Nuclear Medicine and Oncology of Semey, Semey, KazakhstanVanderbilt University Medical Center, Nashville, TennesseeDepartment of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IllinoisHospital Universitario 12 de Octubre, Madrid, SpainIntroduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.http://www.sciencedirect.com/science/article/pii/S2666364322000595COVID-19CancerThoracicNSCLCTERAVOLTRegistry |
| spellingShingle | Christine M. Bestvina, MD Jennifer G. Whisenant, PhD Valter Torri, MD Alessio Cortellini, MD Heather Wakelee, MD Solange Peters, MD, PhD Elisa Roca, MD, PhD Alessandro De Toma, MD Fred R. Hirsch, MD Hirva Mamdani, MD Balazs Halmos, MD Oscar Arrieta, MD Anne-Cecile Metivier, MD Mary J. Fidler, MD Jacobo Rogado, MD Carolyn J. Presley, MD, MHS Celine Mascaux, MD Carlo Genova, MD, PhD Juan Bautista Blaquier, MD Alfredo Addeo, MD Giovanna Finocchiaro, MD Hina Khan, MD Julien Mazieres, MD, PhD Floriana Morgillo, MD, PhD Jair Bar, MD Avinash Aujayeb, MBBS Giannis Mountzios, MD, PhD Vieri Scotti, MD Federica Grosso, MD Erica Geraedts, MD Ardak N. Zhumagaliyeva, MD, PhD Leora Horn, MD Marina Chiara Garassino, MD Javier Baena, MD Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis JTO Clinical and Research Reports COVID-19 Cancer Thoracic NSCLC TERAVOLT Registry |
| title | Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis |
| title_full | Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis |
| title_fullStr | Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis |
| title_full_unstemmed | Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis |
| title_short | Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis |
| title_sort | coronavirus disease 2019 outcomes patient vaccination status and cancer related delays during the omicron wave a brief report from the teravolt analysis |
| topic | COVID-19 Cancer Thoracic NSCLC TERAVOLT Registry |
| url | http://www.sciencedirect.com/science/article/pii/S2666364322000595 |
| work_keys_str_mv | AT christinembestvinamd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT jennifergwhisenantphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT valtertorrimd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT alessiocortellinimd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT heatherwakeleemd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT solangepetersmdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT elisarocamdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT alessandrodetomamd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT fredrhirschmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT hirvamamdanimd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT balazshalmosmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT oscararrietamd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT annececilemetiviermd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT maryjfidlermd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT jacoborogadomd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT carolynjpresleymdmhs coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT celinemascauxmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT carlogenovamdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT juanbautistablaquiermd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT alfredoaddeomd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT giovannafinocchiaromd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT hinakhanmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT julienmazieresmdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT florianamorgillomdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT jairbarmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT avinashaujayebmbbs coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT giannismountziosmdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT vieriscottimd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT federicagrossomd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT ericageraedtsmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT ardaknzhumagaliyevamdphd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT leorahornmd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT marinachiaragarassinomd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis AT javierbaenamd coronavirusdisease2019outcomespatientvaccinationstatusandcancerrelateddelaysduringtheomicronwaveabriefreportfromtheteravoltanalysis |